<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910920-0071</DOCNO><DOCID>910920-0071.</DOCID><HL>   Financing Business:   Centocor Inc.</HL><DATE>09/20/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   CNTO</CO><MS>TECHNOLOGY (TEC)</MS><IN>BOND MARKET NEWS (BON)MEDICAL andamp; BIOTECHNOLOGY, GENETIC RESEARCH, PROSTHETICS (MTC)</IN><NS>BOND MARKET NEWS (BON)</NS><RE>NORTH AMERICA (NME)PENNSYLVANIA (PA)UNITED STATES (US)</RE><LP>   CENTOCOR Inc. said it plans to issue about $100 million ofconvertible subordinated debentures outside the U.S. Thedebentures will be convertible into common shares of theMalvern, Pa., biotechnology company, whose main product isCentoxin, a drug used to treat blood poisoning. Proceeds ofthe offering would be used for manufacturing and marketingcosts of Centoxin, among other operations; clinical testingand development of other drugs; and possible acquisitions.The company's products are based on monoclonal antibodytechnology and are primarily designed to treat cancer andinfectious, cardiovascular and autoimmune diseases. Thedebentures won't be registered in the U.S. and some will bein bearer form, which would be subject to U.S. tax lawrequirements, Centocor said. With some exceptions, it added,the debentures can't be sold, offered or delivered in theU.S.</LP><TEXT/></DOC>